Abzena will be attending the virtual Antibody engineering & therapeutics event from 14th-16th December 2020. If you would like to join us you can register for the event here.
Antibody engineering & therapeutics is the number 1 antibody engineering conference for accelerating next generation antibodies to commercial success.
We will also be presenting at the event. Our Senior Director, Antibody Discovery and Protein Engineering, Rob Holgate will be speaking on Wednesday 16th December 2020 at 8.45am ET/1.45pm GMT on “Addressing the challenges of therapeutic antibody development through the application of Design and Developability”.
Rob’s presentation describes Abzena’s integrated approach to designing and selecting lead drug candidates for development and manufacture. This approach draws on developability concepts established from Abzena’s extensive experience in the field of biologics and bioconjugates.
Benefits of applying developability concepts include:
· Allowing the early identification of risk factors and by doing so, providing scope to apply design alterations to fix/reduce liabilities.
· Reducing the likelihood of major issues arising at a later, more costly, stage of development.
· Selecting the best drug candidate(s) for development